DQ 2556

DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL) . DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins[1][2].

Product Specifications

CAS Number

[102253-70-3]

UNSPSC

12352005

Target

Antibiotic; Bacterial; Penicillin-binding protein (PBP)

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Smiles

[O-]C(C1=C(C[N+]2=CC=C(C3=CN=CO3)C=C2)CS[C@@]([C@@H]4NC(/C(C5=CSC(N)=N5)=N\OC)=O)([H])N1C4=O)=O

Molecular Formula

C22H19N7O6S2

Molecular Weight

541.56

References & Citations

[1]Fujimoto T, et al. In vitro activity of DQ-2556, a new cephalosporin. Antimicrob Agents Chemother. 1986 Oct;30 (4) :611-3. |[2]Ishida Y, et al. In vitro and in vivo activity of DQ-2556, a new cephalosporin. Chemotherapy. 1995 Jan-Feb;41 (1) :5-13.